Expert panelists discuss the essential role of primary care in early skin cancer detection, balancing clinical judgment with emerging AI artificial intelligence tools, and more.

A panelist discusses how Neffy addresses unmet needs through superior temperature stability (tolerating up to 122°F for 3-4 days), extended shelf life (24-30 months), and needle-free administration that eliminates injection-related complications.

A panelist discusses how real-world studies in Japan showed Neffy successfully treated grade 2 anaphylaxis symptoms in pediatric patients with a median resolution time of 16 minutes and minimal adverse effects.

A panelist discusses how FDA bracketing studies demonstrated that Neffy's pharmacokinetics and pharmacodynamics fall within the established safety and efficacy range of existing epinephrine auto-injectors, with rapid onset within one minute.

A panelist discusses how Neffy represents a novel intranasal epinephrine delivery system using three FDA-approved components: epinephrine, Intravail absorption enhancer, and a proven nasal spray device already used in other medications.

A panelist discusses how multiple barriers prevent timely epinephrine use, including patient reluctance to use auto-injectors, lack of device availability, uncertainty about administration timing, and cost concerns, leading to widespread underuse.

A panelist discusses how early epinephrine administration significantly reduces severe complications, prevents progression to life-threatening stages, and decreases the need for additional medical interventions like hospitalization or multiple doses.

A panelist discusses how epinephrine is the first and only evidence-based first-line treatment for anaphylaxis, working through alpha and beta adrenergic receptors to rapidly reverse life-threatening symptoms unlike slower-acting antihistamines.

A panelist discusses how anaphylaxis affects approximately 40 million people in the United States with severe systemic reactions involving multiple organ systems, leading to over 500,000 emergency room visits annually.

Arcutis Biotherapeutics announced today the enrollment of the first patient in the phase 2 INTEGUMENT-INFANT trial.

The novel triple fixed-dose combination of telmisartan, amlodipine and indapamide, is the first of its kind approved for initial treatment of hypertension.